Press release | 11th September 2007
Genmab Expands Use of IDBS' ActivityBase XE Edition in Hybridoma Discovery
Guildford, United Kingdom, September 11, 2007 – IDBS, an industry leading provider of drug discovery data management solutions, today announced that Genmab BV (Utrecht, The Netherlands) has extended its use of ActivityBase Xtended Edition (ActivityBase XE) within its Hybridoma Discovery department. Genmab initially purchased ActivityBase XE in 2006 to handle the design, capture, storage and retrieval of their plate-based screening data. Following the successful implementation, Genmab has more than doubled the number of ActivityBase XE licenses.
With multiple monoclonal antibody products currently in development or under evaluation to treat cancer, inflammatory conditions and infectious diseases, international biotechnology company Genmab sought a data management solution that had the flexibility to handle the data produced from the functional screening of human monoclonal antibody therapies. ActivityBase XE enables scientists at Genmab to capture, validate and visualize the data from antibody screening in a contextually rich environment.
Arnout Gerritsen, Sr. Manager of Lead Identification at Genmab, commented: “The introduction of ActivityBase XE into our Hybridoma Discovery department has significantly improved the efficiency of our human antibody screening campaigns. The flexibility inherent within the ActivityBase XE module enables us to use both Excel and non-Excel templates in our analysis.” He added: “Providing a context around the screening results has promoted a better understanding and enhanced decision-making.”
Neil Kipling, founder and CEO of IDBS, commented: “ActivityBase XE provides additional functionality to the ActivityBase Suite and is designed specifically to address the requirements of time-constrained screening departments. Genmab needed a solution that could adapt to meet the requirements of their hybridoma discovery activities. ActivityBase has the flexibility to handle many different types of screening data making it ideal for this work. As well as support for traditional high-throughput (HTS) and high-content (HCS) screening, ActivityBase XE can also support a wide range of new screening methodologies.” He added: “We are delighted to see Genmab using ActivityBase XE in such a novel way.”